

Washington State Pharmacy and Therapeutics Committee & Drug Utilization Review Board
Meeting by Zoom Webinar
Wednesday, August 13, 2025, 9 a.m. to 4 p.m.

Agenda		
Time	Topic	Presenter
9 a.m.	Welcome & Introductions Pharmacy & Therapeutics (P&T) Committee Convenes (Reviews drug classes for the WA PDL)	Peter Barkett, Committee Chair
	Atopic Dermatitis <ul style="list-style-type: none"> Stakeholder input* Motion 	Beth Shaw, MSc
	TIMs for RA <ul style="list-style-type: none"> Stakeholder input* Motion 	Jennifer Lyon, MS, MLIS, Med, DERP
	TIMs for PsA <ul style="list-style-type: none"> Stakeholder input* Motion 	Courtney Cooper, MPH, DERP
	CGRPs for Headache <ul style="list-style-type: none"> Stakeholder input* Motion 	Jennifer Lyon, MS, MLIS, Med, DERP
	P&T Committee Adjourns Break (10 min)	Peter Barkett, Committee Chair All
	Drug Utilization Review (DUR) Board Convenes (Reviews drug classes for the Apple Health PDL)	Peter Barkett, Committee Chair
	Apple Health Policy: 30.17.00 Endocrine and Metabolic Agents : Somatostatic Agents <ul style="list-style-type: none"> Stakeholder input* Motion 	Ryan Taketomo, HCA
	Apple Health Policy: 30.45.40 Endocrine and Metabolic Agents : Vasopressin Receptor Antagonists - Oral <ul style="list-style-type: none"> Stakeholder input* 	Luke Dearden, HCA

** Stakeholders will be allowed 3 minutes for comments.*

Committee discussion and motions will follow stakeholder comments.

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions
 please call Nonye Connor at 360-725-2044.

	<ul style="list-style-type: none"> • Motion 	
	Apple Health Policy: 30.90.80 Endocrine and Metabolic Agents : Urea Cycle Disorder Agents – Oral <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Marissa Tabile, HCA
	Apple Health Policy: 21.53.20 Oncology Agents : BRAF Kinase Inhibitors – Oral <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Luke Dearden, HCA
	Lunch (30 min)	All
	Apple Health Policy: 21.53.80 Oncology Agents : Phosphatidylinositol 3-Kinase (PI3K) Inhibitors – Oral <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Ryan Taketomo, HCA
	Apple Health Policy: 66.27.00.AL Cytokine and CAM Antagonists: IL-36 Inhibitors <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Marissa Tabile, HCA
	ADHD / Anti-Narcolepsy <ul style="list-style-type: none"> • Dopamine and Norepinephrine Reuptake Inhibitors (DNRIS) • Histamine H3-Receptor Antagonist / Inverse Agonist • Non-Stimulants • Stimulants - Long Acting • Stimulants – Misc • Stimulants - Short Acting <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Nina Huynh, Prime
	Allergy <ul style="list-style-type: none"> • Allergenic Extracts / Biologicals - Oral <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Nina Huynh, Prime
	Antiparkinson Agents <ul style="list-style-type: none"> • Adenosine Receptor Antagonists • Dopaminergics • Monoamine Oxidase Inhibitors (MAOI) <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Nina Huynh, Prime
	Antipsychotics / Antimanic Agents <ul style="list-style-type: none"> • Antipsychotics - 2nd Generation • Antipsychotics – Combinations 	Nina Huynh, Prime

** Stakeholders will be allowed 3 minutes for comments.*

Committee discussion and motions will follow stakeholder comments.

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Nonye Connor at 360-725-2044.

	<ul style="list-style-type: none"> • Parkinsons Psychotic Disorder <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	
	Endocrine And Metabolic Agents <ul style="list-style-type: none"> • Somatostatic Agents <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Nina Huynh, Prime
	Gastrointestinal Agents <ul style="list-style-type: none"> • Ileal Bile Acid Transporter Inhibitors <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Nina Huynh, Prime
	Hematological Agents <ul style="list-style-type: none"> • Compliment Inhibitors - Injectable <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Nina Huynh, Prime
	Neuromuscular Agents <ul style="list-style-type: none"> • Antimyasthenic/Cholinergic Agents <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Nina Huynh, Prime
	Break (10 min)	All
	Oncology Agents <ul style="list-style-type: none"> • Antineoplastics Combinations – Oral • BRAF Kinase Inhibitors – Oral • Cyclin Dependent Kinases (CDK) Inhibitors – Oral • MEK Inhibitors – Oral • Tropomyosin Receptor Kinase Inhibitors – Oral • Tyrosine Kinase Inhibitors – Oral <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Nina Huynh, Prime
	Allergy <ul style="list-style-type: none"> • Antihistamines – Injectable • Misc – Nasal Antidepressants <ul style="list-style-type: none"> • GABA Receptor Modulator - Neuroactive Steroid Antidiabetics <ul style="list-style-type: none"> • Cellular Therapy Atopic Dermatitis Agents <ul style="list-style-type: none"> • Immunosuppressive Agents - Topical Combinations Bone Density Regulators <ul style="list-style-type: none"> • Rank Ligand Inhibitors Cardiovascular Agents <ul style="list-style-type: none"> • Misc 	Marissa Tabile, HCA Nina Huynh, Prime

** Stakeholders will be allowed 3 minutes for comments.*

Committee discussion and motions will follow stakeholder comments.

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Nonye Connor at 360-725-2044.

	<p>Endocrine and Metabolic Agents</p> <ul style="list-style-type: none"> • GAA Deficiency Agents • Growth Hormone Releasing Hormones (GHRH) • Growth Hormones • Mucopolysaccharidosis Agents • Urea Cycle Disorder Agents – Oral • Vasopressin Receptor Antagonists - Oral <p>Gastrointestinal Agents</p> <ul style="list-style-type: none"> • Short Bowel Syndrome <p>Glaucoma Agents</p> <ul style="list-style-type: none"> • Adrenergic Agents • Adrenergic Agents Combinations • Beta – Blockers • Beta - Blockers Combinations • Carbonic Anhydrase Inhibitors • Kinase Inhibitors • Miotics • Prostaglandins <p>Hematological Agents</p> <ul style="list-style-type: none"> • Aminolevulinate Synthase 1-Directed siRNA • Pyruvate Kinase Activators • Stem Cell Mobilizers • Thrombopoiesis (TPO) Stimulating Proteins <p>Neuromuscular Agents</p> <ul style="list-style-type: none"> • Systemic Lupus Erythematosus Agents <p>Oncology Agents</p> <ul style="list-style-type: none"> • Androgen Biosynthesis Inhibitors – Oral • Antiandrogens – Oral • FGFR Kinase Inhibitors – Oral • Hedgehog Pathway Inhibitors – Oral • Methyltransferase Inhibitors – Oral • MTOR Kinase Inhibitors – Oral • Multikinase Inhibitors – Oral • Poly (ADP-Ribose) Polymerase (PARP) Inhibitors – Oral • Retinoids – Oral • Topoisomerase Inhibitors - Oral <p>Ophthalmic Agents</p> <ul style="list-style-type: none"> • Ectoparasitocides • Immunomodulators • Nerve Growth Factors <p>Respiratory Agents</p> <ul style="list-style-type: none"> • Pulmonary Fibrosing Agents <p>Smoking Deterrents</p> <ul style="list-style-type: none"> • Misc - Other <p>Vasopressors</p> <ul style="list-style-type: none"> • Misc - Oral <p>All classes in this section:</p> <ul style="list-style-type: none"> • Stakeholder input* • Motion 	
--	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--

** Stakeholders will be allowed 3 minutes for comments.*

Committee discussion and motions will follow stakeholder comments.

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Nonye Connor at 360-725-2044.

4:00 p.m.	Drug Utilization Review (DUR) Board Adjourns	Peter Barkett, Committee Chair

For all Apple Health (Medicaid) questions:

1. Go to [HCA Support](#).
2. Click **Public**. You will need a SecureAccess Washington (SAW) account. ([View instructions for accessing SAW.](#))
3. Once you have logged into SAW, you will see the HCA Support portal.
4. Click **Make a Request**.
5. Click the **Apple Health Pharmacy** tile. This will take you to the online form.



** Stakeholders will be allowed 3 minutes for comments.*

Committee discussion and motions will follow stakeholder comments.

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Nonye Connor at 360-725-2044.